“
TL;DR
Key findings include that MAFLD-related HCC often occurs in non-cirrhotic livers, complicating surveillance.
Journal of Gastroenterology · 4 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
Key findings include that MAFLD-related HCC often occurs in non-cirrhotic livers, complicating surveillance.
Key findings include that MAFLD-related HCC often occurs in non-cirrhotic livers, complicating surveillance. The review summarizes post-curative therapy outcomes, noting conflicting reports on survival after resection and similar post-transplant outcomes versus other etiologies. A significant focus is the differential response to systemic therapies; meta-analyses suggest immunotherapy may be less effective for non-viral (often MAFLD-related) HCC compared to viral HCC, with potential mechanistic explanations involving immune cell populations. Limitations include reliance on retrospective data and subgroup analyses of non-viral HCC in trials. The review underscores the need for improved surveillance and precision medicine approaches for MAFLD-HCC.